$DFPH

Chernett Jorey purchased $95K of DFPH

Chernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.

Original reporting
SEC EDGAR · Chernett Jorey
Published Jul 22, 2026, 1:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DFPH
Neutral
low confidence
Mentioned
$DFPH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFPHNeutralLow
01

Why it matters

The newest fact is the reported open-market purchase by a 10% owner at a specific price and share count; it may slightly influence sentiment but does not introduce new operational or financial information.

02

Market read

A disclosed insider buy can be monitored, but this filing alone is unlikely to drive a material repricing without accompanying company catalysts.

03

What to watch

The filing does not state intent, timing constraints, or whether the buyer has other positions; traders should avoid extrapolating to fundamentals from one purchase.

Relevance 4/10Novelty 3/10Timing: New Form 4 filed 2026-07-22, covering a 2026-07-21 purchase.

Background

The article is an SEC Form 4 insider transaction disclosure for Oncology Institute, Inc. (DFPH).

Company-level read

Ticker impact

$DFPHNeutralLow confidence
Context

On 2026-07-21, 10% owner Chernett Jorey bought 18,000 shares of DFPH at $5.2700 for about $94,860, per Form 4.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 insider buys can be informative, but the article provides no new company-specific catalyst (no guidance, trial, deal, or regulatory action) and the transaction size is modest relative to typical market moves.

Market effects

No sector-level implications; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider buys under Form 4 can be routine or planned; without a 10b5-1 plan and without follow-on context, the signal may be weak.

Key entities

  • Oncology Institute, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Chernett Jorey

    10% owner who purchased 18,000 shares of DFPH at $5.2700 on 2026-07-21.

Related articles